Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells
- PMID: 12692261
Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells
Abstract
Multidrug resistant (MDR) cancer cells overexpressing P-glycoprotein (P-gp) display variations in invasive and metastatic behavior. We previously reported that these properties of MDR cancer cell lines overexpressing P-gp could be altered by chemotherapeutic drugs or MDR modulators (R. S. Kerbel et al., Cancer Surv., 7: 597-629, 1988). To attempt to clarify the mechanism(s) underlying these observations, we studied the expression of extracellular matrix metalloproteinase inducer (EMMPRIN), a glycoprotein enriched on the surface of tumor cells that can stimulate the production of matrix metalloproteinases (MMPs), in sensitive and MDR cancer cells. Using immunofluorescence staining and fluorescence-activated cell sorting analysis, we found that EMMPRIN expression was increased in MDR carcinoma cell lines, MCF-7/AdrR, KBV-1, and A2780Dx5, as compared to their parental counterparts. The MDR cell lines produced more matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9), as determined by zymography, Western blot, and reverse transcription-PCR. Treatment of MDR cells with an anti-EMMPRIN antibody inhibited the activity of MMP-1, MMP-2, and MMP-9. In MDR cell line MCF-7/AdrR, an increased in vitro invasive ability was observed as compared with the sensitive line MCF-7, and EMMPRIN antibody could inhibit the in vitro invasion in drug-resistant cells. In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk). Our results suggest that during the development of MDR, the expression of EMMPRIN is responsible for the increased activity of MMP in MDR cell lines.
Similar articles
-
Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN.Mol Cancer Res. 2004 Feb;2(2):73-80. Mol Cancer Res. 2004. PMID: 14985463
-
(-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.Biosci Rep. 2011 Apr;31(2):99-108. doi: 10.1042/BSR20090143. Biosci Rep. 2011. PMID: 20446926
-
Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer.World J Surg. 2000 Mar;24(3):334-40. doi: 10.1007/s002689910053. World J Surg. 2000. PMID: 10658069
-
EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair.Biochimie. 2005 Mar-Apr;87(3-4):361-8. doi: 10.1016/j.biochi.2004.09.023. Biochimie. 2005. PMID: 15781323 Review.
-
Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function.Curr Top Dev Biol. 2003;54:371-89. doi: 10.1016/s0070-2153(03)54015-7. Curr Top Dev Biol. 2003. PMID: 12696756 Review. No abstract available.
Cited by
-
CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma.Exp Cell Res. 2012 Aug 15;318(14):1788-98. doi: 10.1016/j.yexcr.2012.04.022. Epub 2012 May 30. Exp Cell Res. 2012. PMID: 22659167 Free PMC article.
-
Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.Br J Cancer. 2010 Sep 28;103(7):1008-18. doi: 10.1038/sj.bjc.6605839. Epub 2010 Aug 24. Br J Cancer. 2010. PMID: 20736947 Free PMC article.
-
Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells.Cancer Sci. 2007 Nov;98(11):1767-74. doi: 10.1111/j.1349-7006.2007.00593.x. Epub 2007 Aug 28. Cancer Sci. 2007. PMID: 17725804 Free PMC article.
-
MMP1-induced NF-κB activation promotes epithelial-mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer.Cell Death Dis. 2025 Apr 26;16(1):346. doi: 10.1038/s41419-025-07615-y. Cell Death Dis. 2025. PMID: 40287412 Free PMC article.
-
Targeting cellular and microenvironmental multidrug resistance.Expert Opin Drug Deliv. 2016 Sep;13(9):1199-202. doi: 10.1080/17425247.2016.1214570. Epub 2016 Aug 5. Expert Opin Drug Deliv. 2016. PMID: 27461854 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous